海角社区

Vadim Gushchin, M.D., serves as Director of The Melanoma and Skin Cancer Center at Mercy as well as Director of Gastrointestinal Oncology, a division of Surgical Oncology at Mercy Medical Center in Baltimore, Maryland. Dr. Gushchin offers expertise in complex malignancies and is a skilled cancer surgeon. He is exceptionally accomplished in minimally invasive surgery – most notably in da Vinci Robotic Surgery – as well as in traditional open surgery techniques. Gastrointestinal Cancer (GI Cancers), melanoma – more commonly known as skin cancer, and thyroid cancer are among the many cancer diagnoses Dr. Gushchin treats. To determine the best treatment option for his surgical oncology patients, Dr. Gushchin carefully evaluates each patient’s risk factors, medical history, current clinical condition, surgical alternatives and post-surgical recovery options in order to fully develop a thorough, personalized care plan. Dr. Gushchin comforts and compassionately walks his patients through the treatment steps needed to care for melanoma, thyroid and parathyroid disease, peritoneal surface malignancies (abdominal tumors), and recurring tumors within the colon, rectum and liver. Dr. Gushchin is well-recognized for his experience in treating complex cancers with HIPEC (Hyperthermic Intraperitoneal Chemotherapy). Dr. Gushchin trained under the internationally renowned surgical oncologist Dr. Paul Sugarbaker to master this procedure, which involves cytoreductive surgery followed by a heated chemotherapy solution to reduce and eliminate tumors. Dr. Gushchin has participated in over 150 HIPEC surgeries and provides patients expertise in complicated HIPEC surgeries including repeat HIPEC surgeries, simultaneous liver resections at the time of HIPEC as well as other advanced surgical treatments in conjunction with HIPEC treatment. An international presenter and teacher, Dr. Gushchin has educated physicians around the world on HIPEC treatment and has organized teaching courses for the treatment of peritoneal surface malignancies (complex abdominal cancers that can be treated with HIPEC). As an extension of his knowledge and compassion, Dr. Gushchin has been instrumental in setting up treatment centers for peritoneal surface malignancies in other parts of the world including Lithuania, Siberia and Ukraine. Dr. Vadim Gushchin is one of Mercy Medical Center’s top surgical oncologists. He utilizes many of the latest innovations in technology and research to provide state-of-the-art treatment options to his patients. Dr. Gushchin brings expertise in robotic surgery, using the da Vinci robot. Patients who qualify for da Vinci robot surgery typically experience the benefits of a more precise and exacting surgery, a less invasive procedure, shorter hospital stay and faster recovery. Dr. Vadim Gushchin leads a multidisciplinary team of experts at The Melanoma and Skin Cancer Center at Mercy to treat a wide range of skin cancers. As an experienced oncology surgeon and talented cancer specialist, he uses the Isolated Limb Infusion technique to try to save an arm or leg that has been aggressively attacked by skin cancer. Isolated Limb Infusion, also known as ILI, offers patients a remarkable alternative approach to metastatic melanoma on a limb. This type of skin cancer commonly leads to amputation or a disfiguring result. Dr. Gushchin and his patients know this doesn’t always have to be the case. Isolated Limb Infusion gives Dr. Gushchin a fighting chance to save his patients’ affected arms and/or legs, reduce or shrink the cancerous tumor and avoid the need for a more radical surgery.

Dr. Camille Stewart was trained in general surgery at the University of Colorado in Aurora, Colorado, and in Complex General Surgical Oncology at City of Hope in Duarte, California. She is an Assistant Professor of Surgery and is the Director of the Melanoma Program within the Department of Surgery.

Sajid Khan, MD is an Associate Professor of Surgery (Oncology), Section Chief of Hepato-Pancreato-Biliary & Mixed Tumors at Yale School of Medicine, and Co-Director of Team Science at Yale Center for Clinical Investigation. Dr. Khan is nationally recognized for superb clinical care and excellence in cancer research. He earned his medical degree from SUNY Upstate Medical University in Syracuse, NY and is Board Certified in both Complex General Surgical Oncology and General Surgery. He completed general surgery training at Oregon Health & Science University in Portland, OR and Albert Einstein College of Medicine/Montefiore in Bronx, NY. He also completed a research fellowship in surgical oncology at Memorial Sloan-Kettering Cancer Center in New York, NY and a clinical and research fellowship in surgical oncology at University of Chicago Medical Center in Chicago, IL. . Dr. Khan is dedicated to improving the lives of cancer patients by his busy surgical practice, federally funded research, leadership by example, and kindness.
Dr. Khan's surgical oncology practice specializes in patients with tumors of the liver, pancreas, bile ducts, gallbladder, stomach, and colon. Additionally he treats individuals diagnosed with melanoma, sarcoma, neuroendocrine tumors, and pancreatic cysts. His commitment to his patients and their families incorporates a multidisciplinary team approach, excellent communication, and state of the art minimally invasive surgery to provide an exceptional patient experience. Nationally, he has been named Top Doctors in American by Castle Connolly and consistently ranks in the top 1 percentile rank for patient satisfaction.
Dr. Khan is a federally funded, well published, surgeon-scientist who uses modern molecular biology (focused on metabolomics and transcriptomics) to improve our understanding and treatment of patients with gastrointestinal cancers. His gastrointestinal surgical oncology focused research has been consistently funded by the National Institutes of Health/National Cancer Institute and incorporates principles of team science. The Khan Lab performs translational scientific research studying cancer metastasis and differences in tumor biology based on race/ethnicity and sex. Using molecular and clinical markers, the Khan Lab studies the scientific underpinnings of liver metastasis and identifies cancer patients who may benefit from liver surgery. In addition, his lab studies the relationship of tumor metabolites and RNA expression with race/ethnicity and sex. He also performs clinical outcomes research for all types of gastrointestinal cancers. His lab's research is regularly presented at national and international scientific meetings, published in prestigious scientific journals, and featured in national media outlets.
Dr. Khan is Chair of the Society of Surgery of the Alimentary Tract (SSAT) Research Committee, on the Editorial Board for the Annals of Surgical Oncology, and Institutional Representative for the Society of University Surgeons (SUS). He is an active member of the Society of Surgery of the Alimentary Tract (SSAT), Society of Surgical Oncology (SSO), Society of University Surgeons (SUS), National Comprehensive Cancer Center (NCCN), American College of Surgeons (ACS), Association for Academic Surgery (AAS), Southwest Oncology Group (SWOG), American Society of Clinical Oncology (ASCO), Yale Center for Clinical Investigation (YCCI), Yale Cancer Center, and Yale School of Medicine Admissions Committee.

Dr. Andrei Nikiforchin is a dedicated surgical oncologist, who graduated from the First Pavlov State Medical University in St. Petersburg, Russia, and further trained across Europe and the United States. He has distinguished himself in various roles, including a Clinical Researcher in Surgical Oncology at Mercy Medical Center in Baltimore, MD, a Medical Writer and Editor at "OncoWiki", and an Expert Consultant at "Prosto Sprosit'". Renowned for his surgical expertise and significant contributions to oncology research, Dr. Nikiforchin has authored multiple peer-reviewed publications. His experience is further amplified by his active participation in various professional consortiums and societies, commitment to community-oriented initiatives, and proficiency in English, Ukrainian, and Russian.
Andrei Nikiforchin, M.D., is a GCP-certified researcher in the Surgical Oncology Department of The Institute for Cancer Care at Mercy Medical Center in Baltimore, Maryland, USA. He received his medical doctor degree at Pavlov First State Medical University in St. Petersburg, Russia, in 2015, and then got two specialties in general surgery and surgical oncology. In 2018 after finishing his work in Clinical Hospital #1 MEDSI in Moscow, Russia, Dr. Nikiforchin moved to the United States and started research at The Institute for Cancer Care at Mercy Medical Center in Baltimore, Maryland. His areas of interest and investigation include gastrointestinal and neuroendocrine tumors, peritoneal surface malignancies, and cytoreductive surgery. Dr. Andrei Nikiforchin is a member of ASCO and SSO since 2019 and RUSSCO since 2021.

Sergei Iugai, is a ECFMG-certified and GCP-certified researcher in the Surgical Oncology Department of the Institute for Cancer Care at Mercy Medical Center in Baltimore, Maryland, USA. His current area of interest - surgical and medical treatment of Peritoneal Surface Malignancies (PSM).

Sergei Iugai am fully trained and qualified medical oncologist with experience in the field of inpatient and outpatient care of patients with solid tumors and hematological malignancies as well as palliative and supportive care in oncology. He received general medical degree at Saint Petersburg State University, Faculty of Medicine. After graduation he got the residency position in Saint Petersburg Pediatric Medical University (Department of Oncology and Radiology) and also went through 2-year postgraduate educational program 'Higher school of oncology' with 5% acceptance rate. His medical oncology expertise was confirmed by passing European Society of Medical Oncology (ESMO) examination in 2022.

---

, is the director of Moores Cancer Center at UC San Diego Health. She provides the overall strategic and intellectual direction for the center’s research programs, administrative structure, and multidisciplinary cancer clinical care. She serves as the principal investigator for the Cancer Center’s support grant sponsored by the National Cancer Institute (NCI).
Simeone, a , partners with academic and clinical leaders to guide cancer research and care and provides counsel to campus and university-level committees. She manages day-to-day operations, including scientific, education, and clinical programs.
Prior to her current role, Simeone served as the director of the Pancreatic Cancer Center and was the associate director of translational research at Perlmutter Cancer Center at New York University Langone Health. She is an internationally renowned pancreatic surgeon and researcher with a long-standing career focused on treating pancreatic cancer and pancreatic cystic tumors. Throughout her career, she has driven innovation in cancer care by building a continuum between scientific discovery and new approaches for cancer detection and treatment. She has published more than 230 studies in leading peer-reviewed journals.
Simeone served as the chair of the scientific and medical advisory board of the Pancreatic Cancer Action Network and is a past president of the American Pancreatic Association and Society of University Surgeons. She is an elected member of the National Academy of Medicine and is a member of the National Cancer Institute (NCI) Pancreatic Cancer Task force and the NCI Cancer Centers Study Section. She also serves on the Board of Directors for the National Comprehensive Cancer Network.
She is the principal investigator and lead of Precision Promise, a national clinical trials consortium focused on next-generation clinical trials for people with pancreatic cancer. She is also the founder of the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an international consortium established to drive the early detection of pancreatic cancer.

, is a board-certified general and plastic surgeon who specializes in all aspects of breast health, with a focus on breast cancer and breast reconstruction. She directs UC San Diego Health's , which offers premier breast cancer detection, diagnosis, and personalized care. Wallace's other specialties include melanoma diagnosis and treatment, as well as all forms of cosmetic breast and body contouring surgery. Wallace also has expertise in providing gender-affirming care to transgender and nonbinary patients.
Wallace is a professor in the University of California San Diego School of Medicine Department of Surgery and is very involved in teaching medical students, residents, fellows and colleagues. Her research focus has been in the development of molecular targeted imaging agents used for the detection of breast cancer and melanoma. She has also led the breast health center team in building a large scale clinical trials program, including novel neoadjuvant therapies and risk management.
Wallace is sought for her presentations on breast health, prevention, surgical intervention and reconstruction by local and national organizations. She also contributes professionally to many cancer leadership services and UC San Diego committees and is a member of the .